ISSN: 1080-6059
Jan Clement,* Guy H Neild,† Piet Maes,* Herwig Leirs,‡ Patrick Matthys,* and Marc Van Ranst*
*University of Leuven, Leuven, Belgium; †Royal Free Hospital, London, United Kingdom; and ‡University of Antwerp, Antwerp, Belgium
Suggested citation for this article
To the Editor: In a recent letter (1), dos Santos et al. described 3 cases of hantavirus pulmonary syndrome (HPS) from Juquitiba and stated that "the first human cases of symptomatic infection by hantaviruses were reported from Brazil in 1993." However, we described 8 cases of symptomatic hemorrhagic fever with renal syndrome (HFRS) in Recife, Brazil, 5 months before the initial May 1993 report of Sin Nombre virus (SNV)–induced HPS in the United States (2). Our report was therefore the first published account of symptomatic hantavirus infections, not just in Brazil but anywhere in the Americas (3).
Serum samples from our Brazilian HFRS cases, collected in 1990, were screened by an immunofluorescence assay (IFA) and ELISA for immunoglobulin G, as were the current Brazilian HPS cases (1). Two of our patients had an increased immunoglobulin M titer by ELISA (2). Rat-transmitted Seoul virus (SEOV) was considered most likely because this was the only hantavirus strain showing clear positive results in IFA (2,3). All the Recife cases in 1990 had reported likely rat contacts and were initially diagnosed as leptospirosis with acute renal failure and thrombocytopenia, clinical hallmarks of both HFRS and leptospirosis (3). We also subsequently found evidence of SEOV infection in 31 (15%) of 201 leptospirosis-suspected acute renal failure cases from Belém, Brazil, confirmed in 1 case with highly specific neutralization tests (4). Moreover, as we predicted (3), some of the 133 (41%) of 326 urban cases of acute renal failure from Salvador, Brazil, which appeared nonconfirmed for leptospirosis (5), were later shown to be caused by SEOV (unpub. data). Finally, of 379 schoolchildren from Salvador at high risk for frequent rat exposure, 13.2% were IFA positive for the Korean prototype Hantaan virus (HTNV) but none for the American SNV (6). Because both HTNV and its rodent reservoir are absent from the American biotope, HTNV seroreactivity should be considered a cross-reaction to another related murine antigen; that is to say, the ratborne SEOV.
Wild rats (Rattus rattus and R. norvegicus) are the only Old World rodents ubiquitous in the New World and thus a potential source of SEOV infection in the Americas (3,7). Moreover, the first hantavirus characterized in South America was SEOV, isolated as long ago as 1984 from a rat caught in Belém (7). Furthermore, the first 3 clinical cases of hantavirus infection in the United States were SEOV-induced (Baltimore rat virus) HFRS cases and not HPS (8).
The clinical syndromes of HFRS and HPS can appear identical, with pulmonary edema, shock, and renal insufficiency with marked proteinuria and thrombocytopenia (9). Moreover, worldwide ELISA testing with a single antigen such as SNV or Puumala virus (PUUV) can result in misleading cross-reactions, since both viruses are genetically related. Although this SNV-PUUV cross-reactivity enabled the first recognition of HPS cases in the New World 14 years ago, this may now lead to the wrong clinical diagnosis and reinforces the need for specific tests such as neutralization tests or reverse transcription–PCR. Although not as lethal and probably not so frequent as HPS, SEOV-induced HFRS may still be greatly underestimated in the Americas, or misdiagnosed as leptospirosis.
Clement J, Neild GH, Maes P, Leirs H, Matthys P, Van Ranst M. Symptomatic human hantavirus in the Americas [letter]. Emerg Infect Dis [serial on the Internet]. 2007 Feb [date cited]. Available from http://www.cdc.gov/EID/content/13/2/345.htm
Please use the form below to submit correspondence to the authors or contact them at the following address:
Jan Clement, Hantavirus Reference Centre, Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, B3000 Leuven, Belgium; email: jan.clement@uz.kuleuven.ac.be
Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.
Please contact the EID Editors at eideditor@cdc.gov
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
This page posted January 23, 2007
This page last reviewed January 24, 2007
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435